Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
DURHAM, N.C., March 30, 2016 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer, will participate in the 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference being held Thursday, March 31, 2016 at the Apella Event Space at Alexandria Center in New York City. Dr. Schreiber will join a panel discussion starting at 11:00 a.m. ET entitled “Therapeutic Cancer Vaccines: Stimulating the Immune System,” as well as a second panel discussion starting at 4:30 p.m. ET entitled “Combination Immuno-Oncology Themes.”
The conference is hosted by MaidStone Life Sciences, LLC and William Blair & Company, LLC. For more information, please visit http://www.maidstonels.com/conference.html.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
